What is ELVN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.89B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ELVN?

P/E (TTM) is n/a and 52-week range is $14.79 to $62.32 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ELVN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ELVN?

The company profile lists net income (TTM) near $-116M, EPS (TTM) near $-1.67 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Enliven Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boulder, Colorado, US, 69.8M shares outstanding, ISIN US29337E1029 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Enliven Therapeutics Inc

$ELVN

Health Care · Pharmaceuticals

IR Run Scenarios

$39.49

-3.31%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 60 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Employees

Website

www.enliventherapeutics.com/

IPO

2020-03-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)